Is NUVL or NVO more undervalued in 2026?

CirclFi compares Nuvalent, Inc. (NUVL) and Novo Nordisk A/S (NVO) using 13 institutional-grade valuation models. NUVL has a Quality of Company score of 3.7/10 while NVO scores 10.0/10.

Which is a better buy — NUVL or NVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NUVL and NVO valuations compare?

NUVL at $110.39 and NVO at $45.58 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NUVL vs NVO Valuation Comparison 2026 — Intrinsic Value Analysis

NUVL

Pharmaceutical Preparations

Nuvalent, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$110.39

Last close

Models

10/13

Active

NVO

Pharmaceutical Preparations

Novo Nordisk A/S

Quality

10.0

out of 10

Value Trap

SAFE

Price

$45.58

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	NUVL Fair Value	NUVL Upside	NVO Fair Value	NVO Upside
Bayesian DCF	Intrinsic	$31.18	-71.8%	$31.49	-30.9%
Earnings Power Value	Intrinsic	$45.79	-56.2%	$44.06	-3.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NUVL vs NVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NUVL vs NVO — Which Stock Is More Undervalued?

NVO scores higher with a 10.0/10 quality rating vs NUVL's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvalent, Inc. (NUVL) and Novo Nordisk A/S (NVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NUVL currently trades at $110.39 with a QOC of 3.7/10, while NVO trades at $45.58 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).